Cigna officer plans $175K sale of 617 shares

An officer of Cigna Group has filed a Rule 144 notice to sell 617 vested restricted shares of common stock.

Rhea-AI Filing Summary

Cigna Group (CI) has a planned sale of common stock reported under Rule 144 for the account of officer Neville Everett. The notice covers 617 shares of common stock that were acquired through restricted stock vesting from the issuer as compensation on March 1, 2026, with an intended sale date around September 3, 2026 and an indicated aggregate value of $175,258.85.

Key Figures

Shares to be sold: 617 shares Aggregate value: $175,258.85 Planned sale date: September 3, 2026 +2 more

5 metrics

Shares to be sold 617 shares Planned Rule 144 sale of Cigna Group common stock

Aggregate value $175,258.85 Estimated value for 617 shares to be sold under Rule 144

Planned sale date September 3, 2026 Approximate date of Rule 144 sale on NYSE

Acquisition date March 1, 2026 Date restricted stock vested as compensation from issuer

Security title Common stock Cigna Group equity security covered by Form 144

Key Terms

Rule 144, Restricted Stock Vesting, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 03/01/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Frank Neville"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing disclose for Cigna Group (CI)?

The filing discloses a planned Rule 144 sale of 617 shares of Cigna Group common stock for the account of officer Neville Everett, with the shares acquired via restricted stock vesting as compensation and an indicated aggregate value of $175,258.85.

How many Cigna Group (CI) shares are covered by this Form 144?

The notice covers 617 shares of Cigna Group common stock. These shares were acquired from the issuer through restricted stock vesting as compensation on March 1, 2026 and are planned for sale under Rule 144.

What is the approximate value of the Cigna Group (CI) shares to be sold?

The Form 144 lists an aggregate value of $175,258.85 for the 617 shares of Cigna Group common stock to be sold through Fidelity Brokerage Services LLC on the NYSE under Rule 144.

When were the Cigna Group (CI) shares acquired and how?

The 617 shares of Cigna Group common stock were acquired on March 1, 2026 through Restricted Stock Vesting from the issuer as compensation, according to the Form 144 disclosure.

When is the planned sale date for the Cigna Group (CI) shares in this Form 144?

The Form 144 indicates an approximate sale date of September 3, 2026 for the 617 shares of Cigna Group common stock to be sold on the NYSE through Fidelity Brokerage Services LLC under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 11:08 AM Accepted by SEC EDGAR 09/03/2026 - 11:08 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001641142
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Cigna Group
SEC File Number	001-38769
Address of Issuer	900 COTTAGE GROVE ROAD BLOOMFIELD CONNECTICUT 06002
Phone	8602266000
Name of Person for Whose Account the Securities are To Be Sold	Neville Everett
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	617	175258.85	264240486	09/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2026	Restricted Stock Vesting	Issuer			617	03/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Frank Neville
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)